How GlaxoSmithKline plc Will Deliver Its Dividend

What can investors expect from GlaxoSmithKline plc (LON:GSK)’s dividend?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m looking at some of your favourite FTSE 100 companies and examining how each will deliver their dividends.

Today, I’m putting GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) under the microscope.

Dividend policy

GSK’s current dividend policy has been around for some years. Management said within the company’s 2012 annual report:

“Free cash flow is available to invest in the business or to return to shareholders consistent with maintaining our targeted credit profile. The priority is to cover the dividend but we intend free cash flow above and beyond this requirement to be available for share buybacks or bolt-on acquisitions, wherever the most attractive returns are available”.

Delivery of the policy

The table below shows the dividends shareholders have received and the growth of their income over the past four years.

  2009 2010 2011 2012
Dividend per share 61p 65p 70p 74p
Dividend growth 7.0% 6.6% 7.7% 5.7%

As you can see, shareholders have done rather well, with annual income increases comfortably ahead of inflation. But let’s look at some of the other key numbers to which management refers in relation to the dividend policy

  2009 2010 2011 2012 H1 2013
Free cash flow (£bn) 5.3 4.5 4.1 2.1 1.7
Dividends (£bn) 3.0 3.2 3.4 3.8 1.9
Share buybacks (£bn) 0.0 0.0 2.2 2.5 0.4
Net debt (£bn) 9.4 8.9 9.0 14.0 15.7

GSK’s free cash flow (FCF) has declined annually between 2009 and 2012. A particularly large drop during 2012 to £2.1bn meant the company fell short on the board’s “priority” for FCF “to cover the dividend”; the dividend was £3.8bn.

Furthermore, while management has said that FCF “above and beyond” the dividend payout would be available for share buybacks, the company has, in fact, bought back shares only partly covered by FCF (after the dividend) during 2011 and wholly in excess of FCF during 2012. This is reflected in the £5bn leap in net debt between 2011 and 2012.

GSK’s interim results announced last week showed first-half dividends (£1.9bn) again uncovered by FCF (£1.7bn), share buybacks continuing (£0.4bn) and a further rise in debt (to £15.7bn).

What’s ahead?

Is GSK’s dividend safe? Well, it certainly doesn’t look as safe as it did three or four years ago. However, management has a few weapons in the armoury to raise more cash, including the sale of non-core brands Lucozade and Ribena — expected to happen this year — which could generate £1.5bn or more. The company can also take on more debt. Despite increasing its borrowings substantially of late, finance costs have not risen a great deal because interest rates are so low.

Essentially, GSK has to perform a bit of a balancing act to keep the dividend growing until some of the drugs within its strong pipeline — including nine in final (Phase III) trials — come to market. While the company doesn’t have the most secure dividend around, City analysts are generally of the view that GSK’s management will deliver. The consensus is for a 4.5% uplift in the dividend this year, followed by a 6% rise for 2014.

Finally, let me finish by saying that if you already own shares in GSK, you may wish to read this free Motley Fool report. You see, GSK is one of five top-notch blue chips that have been pinpointed by our leading analysts as some of the highest-quality businesses you’ll find within the FTSE 100.

This free report can be yours right now with no further obligation — simply click here.

> G A Chester does not own any shares mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Up 75% in 5 years, I reckon this FTSE 250 still has lots to give!

Our writer explains why this FTSE 250 stock could still continue to provide growth and returns despite already being on…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 high-quality FTSE 250 stocks to consider buying

The FTSE 250 is home to some of the best investment opportunities out there. This Fool highlights two stocks for…

Read more »

Investing Articles

The Marks and Spencer share price dips! Is this my chance to buy?

Marks and Spencer was one of the hottest stocks on the market last year. With its share price falling in…

Read more »

Growth Shares

How low could the boohoo share price go?

Jon Smith explains why the enterprise value and the low risk of bankruptcy should help to prevent the boohoo share…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Down 23% in a year! Can the Diageo share price regain £30 in 2024?

This Fool UK writer is checking the charts to see if the Diageo share price can recover from the recent…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

I wouldn’t touch this FTSE 100 stalwart with a bargepole

Despite looking like a bargain on paper, this Fool is avoiding FTSE 100 constituent Vodafone at all costs. Here he…

Read more »

Investing Articles

I’m waiting for the Rolls-Royce share price to pull back before I buy

The Rolls-Royce share price has been the Footsie's best performer in the last year. But this Fool has no intention…

Read more »

Front view photo of a woman using digital tablet in London
Dividend Shares

2 dividend stocks to take me from £0 to £9.5k in second income

Jon Smith talks through some ideas with second income potential, including one stock that has a dividend yield above 10%…

Read more »